Synopsis on recent 10q- the good/bad/ugly...
seems like they are trying to get the 15c2-11 done to get back to Pink current status..
For a Pink Sheet company, there are a few genuinely interesting positives, but the balance sheet, dilution structure, reporting quality, and repeated forward promises make this an extremely speculative turnaround.
One important clarification: this is not an SEC-filed 10-Q in the normal sense. It is an OTC Markets Pink Basic Disclosure quarterly report, and the financials are unaudited. The filing lists no accountant/auditor in the outside-provider section.
My overall read
I'd characterize RMHB right now as:
Operational turnaround attempt + highly leveraged/dilutive capital structure + extremely weak liquidity + potentially meaningful catalysts if management actually delivers.
The bull case is not the $29K reported net income. The real bull case is that RMHB:
1) gets 15c2-11 completed,
2) converts several million dollars of debt into equity at favorable prices,
3) gets the new products/brands actually selling, and
4) finally produces the revenue ramp management has repeatedly forecast.
If those four happen, the company's financial condition could look radically different within a couple quarters.
But we're nowhere near proving that yet.
The positives
1. Operating losses have almost disappeared
This is probably the best hard-number improvement in the filing.
For the first six months:
6M 2025 6M 2026 Change
Revenue $241,651 $110,266 -54%
Gross profit $152,797 $79,942 -48%
G&A $185,914 $82,461 -56%
Operating loss $(33,117) $(2,519) major improvement
Net income $(33,117) +$29,148 positive
So management has actually accomplished something important: expenses fell faster than revenue.
Operating loss went from $33K to only $2.5K despite revenue being cut by more than half.
That's meaningful.
But the $29K net profit is misleading because it included a $31,667 gain on extinguishment of debt. Without that, they're basically breakeven/slightly negative.
2. Cash burn improved dramatically
Operating cash flow:
H1 2025: -$574,441
H1 2026: -$60,115
That's roughly a 90% reduction in operating cash burn.
This is arguably more meaningful than reported earnings.
3. No common-share dilution during H1 2026
Common shares stayed at:
909,496,003 on Dec. 31, 2025
909,496,003 on June 30, 2026
That's notable for a sub-penny Pink Sheet with convertible debt.
Historically, however, dilution has been enormous: the filing shows only 347.9M shares outstanding at the end of 2021, versus 909.5M today.
So I give them credit for six months of stability—but I wouldn't assume the dilution problem has disappeared.
4. Stockholders' deficit is improving
It went from:
-$3.041M → -$2.786M
That's about a $255K improvement in six months.
Still ugly, but moving in the correct direction.
5. There are actual physical/business assets
This isn't merely a corporate shell.
They report:
~$1.0M net property/equipment
~$540K inventory
~$70K receivables
$344K intangibles
$580K goodwill
private-label/co-packing operations
Great Choice/electrolyte products
hydrogen-water project with Dr. Nicholas Perricone
additional proposed brands/products
Total reported assets are $2.68M, up from $2.34M at year-end.
I'd heavily discount goodwill and intangibles when valuing the company, though.
???? The potentially BIG positive: proposed debt restructuring
This caught my attention more than anything else.
Management says RMHB has $2.551M of convertible notes, and claims holders representing at least $1.8M are seriously considering converting at $0.01/share.
That would mean approximately:
$1.8M debt eliminated
÷ $0.01
= 180M new shares
Management contrasts that with roughly 850M shares if converted around $0.003.
Then there's another proposal:
At least $1M of the $1.709M "Loans Payable – Other" would be purchased/converted into shares at $0.01.
That would add another:
100M shares
So if both happen:
Current OS: 909.5M
New shares: ~280M
Pro forma OS: ~1.1895B
That's ~31% dilution to current shares.
BUT—you potentially eliminate $2.8M of debt.
For a company this distressed, I'd actually view that trade as potentially very positive, especially if the market price is materially below $0.01.
The key phrase, though, is "seriously considering."
It hasn't happened.
That's a gigantic distinction.
MAJOR CONCERN #1 — They have essentially NO CASH
This is the scariest hard number:
Cash = $6,058.
Not $600K.
Six thousand dollars.
Against:
Current assets: $753,548
Current liabilities: $5,289,297
Working-capital deficit:
-$4,535,749
The company itself acknowledges this in its going-concern discussion.
This company currently cannot survive on its balance sheet without some combination of:
new capital + debt-holder cooperation + stock issuance + dramatically higher revenue.
That's fundamental.
#2 — Convertible debt/dilution remains enormous
The filing calculates 476,755,966 potential common-stock equivalents, including approximately:
405.7M shares from convertible notes
70M warrants
plus preferred conversions.
Against 909.5M shares currently outstanding.
So existing potential equivalents represent roughly another:
52% of the existing share count.
And authorized common is:
3 BILLION shares
Meaning management has plenty of room to issue substantially more stock.
For a Pink Sheet, that matters enormously.
#3 — Some convertible terms are toxic-looking
This deserves attention.
Some historical notes aren't simply fixed-price conversions.
For example, Eagle Equities notes disclosed conversion at:
40% of the lowest closing price in the previous 20 trading days.
That is classic death-spiral-type convertible financing economics.
The company also reports a $1.683M derivative liability associated with conversion features.
That's why I wouldn't merely ask:
"How much convertible debt is left?"
I'd want a complete current table identifying exactly which notes remain outstanding and their individual conversion formulas.
That's critical.
#4 — Revenue is tiny and going BACKWARDS
This is probably my biggest operational concern.
For six months:
2025: $241,651
2026: $110,266
Down 54%.
Q2 alone:
2025: $63,202
2026: $26,279
That is minuscule.
The business supposedly has manufacturing/co-packing capabilities and a facility/equipment base capable of substantially more volume.
Yet they're producing only about:
$18K/month average revenue in H1.
That's nowhere close to proving the business model.
#5 — Management has a history of forecasts that don't materialize on schedule
This filing itself demonstrates the problem.
There are references to:
production ready July 2024
then potentially August 2024.
Then:
targeting revenue over $1.3M/month by May/June 2024.
Actual revenue during the entire first six months of 2026 was:
$110,266.
The filing even contains outdated language saying:
"achieve profitable operations in 2024"
inside a report covering June 2026.
That seriously reduces the value I assign to forward-looking statements.
Therefore when they now say:
"Starting in October 2026, the company's overall revenue will cover its total burn rate with a profit."
I assign very little valuation credit to that today.
Show me October/November revenue.
#6 — Financial statement quality gives me concerns
Several things jumped out.
The filing says the statements are unaudited.
There's no outside accountant/auditor listed.
And some numbers/disclosures appear inconsistent.
For example, the balance sheet shows:
Derivative liabilities: $(1,683,494)
rather than a conventional positive liability presentation.
The inventory note also lists:
Finished goods: $75,069.55
Raw materials/packaging: $539,919
and then reports total inventory as:
$539,919
Those numbers don't reconcile unless there's something inadequately explained.
There are also inconsistencies in preferred-share descriptions between the disclosure section and financial-statement notes.
For a NYSE company I'd call these sloppy.
For a Pink Sheet company, they make me considerably more cautious because we're relying heavily on management-generated financial statements.
#7 — Legal issues
The filing discloses multiple legal matters.
One landlord case claimed roughly $327K in damages.
Another plaintiff sought approximately $100K plus attorneys' fees.
Management says the former-landlord dispute has subsequently been settled/released, which would be positive, but I'd want independent documentation before removing it from the risk column.
15c2-11 could be an important stock catalyst
Management states:
"All 15c2-11 documentation has been submitted to FINRA for review."
For RMHB as a Pink Sheet security, this could matter substantially for quotation/trading accessibility and liquidity.
But again, the filing documents previous delays.
So I would treat:
Submitted ≠ approved/processed/posted.
This is something I'd monitor closely.
The thing that makes RMHB interesting
There is an unusual setup here.
The company's enterprise fundamentals are awful today, but they're potentially approaching a balance-sheet restructuring.
Imagine they actually execute:
$1.8M convertible debt → equity
$1.0M other loans → equity
+$600K-ish new capital by year-end
15c2-11 becomes effective/posted
new brands launch
revenue finally ramps above burn
Suddenly the story looks dramatically different.
You're exchanging severe balance-sheet insolvency risk for dilution—but if the conversions happen at $0.01, that's potentially a very favorable trade for the company.
That's the bull thesis I would watch.
My RMHB scorecard today
Category My read
Expense reduction - Very good
Cash-burn improvement -Very good
Recent OS stability -Good
Debt restructuring potential - Potentially huge
New products - Interesting/unproven
15c2-11 - Potential catalyst
Revenue -Terrible
Cash/liquidity - Extremely dangerous
Balance sheet - Very weakConvertible dilution -Major risk
Reporting quality - Concern
Management projections -Low credibility until delivered
Bottom line
I wouldn't dismiss RMHB, which is different from what I'd say about many sub-penny Pink Sheets.
There appears to be an actual turnaround effort underneath the mess. Cutting operating cash burn from ~$574K to ~$60K and nearly eliminating the operating loss are tangible accomplishments.
But the investment thesis right now is almost entirely about what happens NEXT—not what the current business is worth.
The two numbers I'd keep in my head are:
$6,058 cash
versus
$4.54M working-capital deficit.
That tells you the risk.
And the two potential game changers are:
~$2.8M proposed debt-to-equity restructuring
and
actual Q4 revenue/product launches.
For me, the trigger that changes RMHB from "lottery-ticket turnaround" to something legitimately investable would be seeing the debt conversions actually close AND monthly revenue start showing several hundred thousand dollars—not another press release saying it's coming.
One more thing: given that you've followed RMHB for a long time, I think the next analysis should be more useful than simply looking at this quarter in isolation. I can pull their prior 2024/2025 OTC filings and press releases and build a "Management Said vs. Actually Delivered" timeline, then calculate RMHB's fully diluted share count under the $0.01 restructuring scenario and what the stock would be worth at $0.005 / $0.01 / $0.02 / $0.05. That would tell us whether this turnaround has asymmetric upside or is mostly another dilution cycle.
seems like they are trying to get the 15c2-11 done to get back to Pink current status..
For a Pink Sheet company, there are a few genuinely interesting positives, but the balance sheet, dilution structure, reporting quality, and repeated forward promises make this an extremely speculative turnaround.
One important clarification: this is not an SEC-filed 10-Q in the normal sense. It is an OTC Markets Pink Basic Disclosure quarterly report, and the financials are unaudited. The filing lists no accountant/auditor in the outside-provider section.
My overall read
I'd characterize RMHB right now as:
Operational turnaround attempt + highly leveraged/dilutive capital structure + extremely weak liquidity + potentially meaningful catalysts if management actually delivers.
The bull case is not the $29K reported net income. The real bull case is that RMHB:
1) gets 15c2-11 completed,
2) converts several million dollars of debt into equity at favorable prices,
3) gets the new products/brands actually selling, and
4) finally produces the revenue ramp management has repeatedly forecast.
If those four happen, the company's financial condition could look radically different within a couple quarters.
But we're nowhere near proving that yet.
The positives
1. Operating losses have almost disappeared
This is probably the best hard-number improvement in the filing.
For the first six months:
6M 2025 6M 2026 Change
Revenue $241,651 $110,266 -54%
Gross profit $152,797 $79,942 -48%
G&A $185,914 $82,461 -56%
Operating loss $(33,117) $(2,519) major improvement
Net income $(33,117) +$29,148 positive
So management has actually accomplished something important: expenses fell faster than revenue.
Operating loss went from $33K to only $2.5K despite revenue being cut by more than half.
That's meaningful.
But the $29K net profit is misleading because it included a $31,667 gain on extinguishment of debt. Without that, they're basically breakeven/slightly negative.
2. Cash burn improved dramatically
Operating cash flow:
H1 2025: -$574,441
H1 2026: -$60,115
That's roughly a 90% reduction in operating cash burn.
This is arguably more meaningful than reported earnings.
3. No common-share dilution during H1 2026
Common shares stayed at:
909,496,003 on Dec. 31, 2025
909,496,003 on June 30, 2026
That's notable for a sub-penny Pink Sheet with convertible debt.
Historically, however, dilution has been enormous: the filing shows only 347.9M shares outstanding at the end of 2021, versus 909.5M today.
So I give them credit for six months of stability—but I wouldn't assume the dilution problem has disappeared.
4. Stockholders' deficit is improving
It went from:
-$3.041M → -$2.786M
That's about a $255K improvement in six months.
Still ugly, but moving in the correct direction.
5. There are actual physical/business assets
This isn't merely a corporate shell.
They report:
~$1.0M net property/equipment
~$540K inventory
~$70K receivables
$344K intangibles
$580K goodwill
private-label/co-packing operations
Great Choice/electrolyte products
hydrogen-water project with Dr. Nicholas Perricone
additional proposed brands/products
Total reported assets are $2.68M, up from $2.34M at year-end.
I'd heavily discount goodwill and intangibles when valuing the company, though.
???? The potentially BIG positive: proposed debt restructuring
This caught my attention more than anything else.
Management says RMHB has $2.551M of convertible notes, and claims holders representing at least $1.8M are seriously considering converting at $0.01/share.
That would mean approximately:
$1.8M debt eliminated
÷ $0.01
= 180M new shares
Management contrasts that with roughly 850M shares if converted around $0.003.
Then there's another proposal:
At least $1M of the $1.709M "Loans Payable – Other" would be purchased/converted into shares at $0.01.
That would add another:
100M shares
So if both happen:
Current OS: 909.5M
New shares: ~280M
Pro forma OS: ~1.1895B
That's ~31% dilution to current shares.
BUT—you potentially eliminate $2.8M of debt.
For a company this distressed, I'd actually view that trade as potentially very positive, especially if the market price is materially below $0.01.
The key phrase, though, is "seriously considering."
It hasn't happened.
That's a gigantic distinction.
MAJOR CONCERN #1 — They have essentially NO CASH
This is the scariest hard number:
Cash = $6,058.
Not $600K.
Six thousand dollars.
Against:
Current assets: $753,548
Current liabilities: $5,289,297
Working-capital deficit:
-$4,535,749
The company itself acknowledges this in its going-concern discussion.
This company currently cannot survive on its balance sheet without some combination of:
new capital + debt-holder cooperation + stock issuance + dramatically higher revenue.
That's fundamental.
#2 — Convertible debt/dilution remains enormous
The filing calculates 476,755,966 potential common-stock equivalents, including approximately:
405.7M shares from convertible notes
70M warrants
plus preferred conversions.
Against 909.5M shares currently outstanding.
So existing potential equivalents represent roughly another:
52% of the existing share count.
And authorized common is:
3 BILLION shares
Meaning management has plenty of room to issue substantially more stock.
For a Pink Sheet, that matters enormously.
#3 — Some convertible terms are toxic-looking
This deserves attention.
Some historical notes aren't simply fixed-price conversions.
For example, Eagle Equities notes disclosed conversion at:
40% of the lowest closing price in the previous 20 trading days.
That is classic death-spiral-type convertible financing economics.
The company also reports a $1.683M derivative liability associated with conversion features.
That's why I wouldn't merely ask:
"How much convertible debt is left?"
I'd want a complete current table identifying exactly which notes remain outstanding and their individual conversion formulas.
That's critical.
#4 — Revenue is tiny and going BACKWARDS
This is probably my biggest operational concern.
For six months:
2025: $241,651
2026: $110,266
Down 54%.
Q2 alone:
2025: $63,202
2026: $26,279
That is minuscule.
The business supposedly has manufacturing/co-packing capabilities and a facility/equipment base capable of substantially more volume.
Yet they're producing only about:
$18K/month average revenue in H1.
That's nowhere close to proving the business model.
#5 — Management has a history of forecasts that don't materialize on schedule
This filing itself demonstrates the problem.
There are references to:
production ready July 2024
then potentially August 2024.
Then:
targeting revenue over $1.3M/month by May/June 2024.
Actual revenue during the entire first six months of 2026 was:
$110,266.
The filing even contains outdated language saying:
"achieve profitable operations in 2024"
inside a report covering June 2026.
That seriously reduces the value I assign to forward-looking statements.
Therefore when they now say:
"Starting in October 2026, the company's overall revenue will cover its total burn rate with a profit."
I assign very little valuation credit to that today.
Show me October/November revenue.
#6 — Financial statement quality gives me concerns
Several things jumped out.
The filing says the statements are unaudited.
There's no outside accountant/auditor listed.
And some numbers/disclosures appear inconsistent.
For example, the balance sheet shows:
Derivative liabilities: $(1,683,494)
rather than a conventional positive liability presentation.
The inventory note also lists:
Finished goods: $75,069.55
Raw materials/packaging: $539,919
and then reports total inventory as:
$539,919
Those numbers don't reconcile unless there's something inadequately explained.
There are also inconsistencies in preferred-share descriptions between the disclosure section and financial-statement notes.
For a NYSE company I'd call these sloppy.
For a Pink Sheet company, they make me considerably more cautious because we're relying heavily on management-generated financial statements.
#7 — Legal issues
The filing discloses multiple legal matters.
One landlord case claimed roughly $327K in damages.
Another plaintiff sought approximately $100K plus attorneys' fees.
Management says the former-landlord dispute has subsequently been settled/released, which would be positive, but I'd want independent documentation before removing it from the risk column.
15c2-11 could be an important stock catalyst
Management states:
"All 15c2-11 documentation has been submitted to FINRA for review."
For RMHB as a Pink Sheet security, this could matter substantially for quotation/trading accessibility and liquidity.
But again, the filing documents previous delays.
So I would treat:
Submitted ≠ approved/processed/posted.
This is something I'd monitor closely.
The thing that makes RMHB interesting
There is an unusual setup here.
The company's enterprise fundamentals are awful today, but they're potentially approaching a balance-sheet restructuring.
Imagine they actually execute:
$1.8M convertible debt → equity
$1.0M other loans → equity
+$600K-ish new capital by year-end
15c2-11 becomes effective/posted
new brands launch
revenue finally ramps above burn
Suddenly the story looks dramatically different.
You're exchanging severe balance-sheet insolvency risk for dilution—but if the conversions happen at $0.01, that's potentially a very favorable trade for the company.
That's the bull thesis I would watch.
My RMHB scorecard today
Category My read
Expense reduction - Very good
Cash-burn improvement -Very good
Recent OS stability -Good
Debt restructuring potential - Potentially huge
New products - Interesting/unproven
15c2-11 - Potential catalyst
Revenue -Terrible
Cash/liquidity - Extremely dangerous
Balance sheet - Very weakConvertible dilution -Major risk
Reporting quality - Concern
Management projections -Low credibility until delivered
Bottom line
I wouldn't dismiss RMHB, which is different from what I'd say about many sub-penny Pink Sheets.
There appears to be an actual turnaround effort underneath the mess. Cutting operating cash burn from ~$574K to ~$60K and nearly eliminating the operating loss are tangible accomplishments.
But the investment thesis right now is almost entirely about what happens NEXT—not what the current business is worth.
The two numbers I'd keep in my head are:
$6,058 cash
versus
$4.54M working-capital deficit.
That tells you the risk.
And the two potential game changers are:
~$2.8M proposed debt-to-equity restructuring
and
actual Q4 revenue/product launches.
For me, the trigger that changes RMHB from "lottery-ticket turnaround" to something legitimately investable would be seeing the debt conversions actually close AND monthly revenue start showing several hundred thousand dollars—not another press release saying it's coming.
One more thing: given that you've followed RMHB for a long time, I think the next analysis should be more useful than simply looking at this quarter in isolation. I can pull their prior 2024/2025 OTC filings and press releases and build a "Management Said vs. Actually Delivered" timeline, then calculate RMHB's fully diluted share count under the $0.01 restructuring scenario and what the stock would be worth at $0.005 / $0.01 / $0.02 / $0.05. That would tell us whether this turnaround has asymmetric upside or is mostly another dilution cycle.
6
